News and Trends 3 Nov 2022 Senescent cells as vaccines against cancer? Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor. This means immune cells cannot reach the cancer cells to remove them. The scientific community has been working to increase the effectiveness of […] November 3, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome. The international, randomized, double-blind, placebo-controlled, phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s […] November 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 VectorBuilder to build gene delivery campus after $57M funding Gene delivery technology company VectorBuilder Inc. has announced the completion of $57 million in funding. The funding, co-led by Legend Capital, will support the construction of VectorBuilder’s new Gene Delivery Research and Manufacturing Campus, and further boost the company’s R&D capabilities and global business presence. VectorBuilder was established in 2014 to commercialize its novel e-commerce […] November 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 CV6 Therapeutics raises $9.2M to test cancer drug CV6 Therapeutics has secured $9.2m to progress its lead oncology asset, CV6-168, into a first-in-human phase 1a clinical trial and perform further scientific development work. CV6 Therapeutics is a drug development biotechnology company specializing in innovative small molecule therapeutics for cancer and inflammatory diseases. Investors participating in the financing include QUBIS, the commercialization arm of […] November 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Alkermes to separate oncology business Alkermes plc is to explore separating its commercial-stage neuroscience business and development-stage oncology business. The company, its board and external financial and legal advisors plan to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business. Alkermes said […] November 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 New therapeutic strategy to improve treatment of aggressive endometrial cancer Endometrial cancer (EC) is the most common type of gynecological cancer and is the fourth most common type of tumor in women in developed countries. Although it has a good prognosis if detected early, advanced and aggressive cases have a high mortality rate and are often resistant to standard chemotherapy treatments. Now, a study published […] November 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Could DNA nanotransporters treat cancer? A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA 20,000 times smaller than a human hair. The DNA nanotransporters could improve how cancers and other diseases are treated. Reported in a new study in Nature Communications, the molecular transporters can be chemically […] November 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Avista Capital Partners acquires Taconic Biosciences Private equity company Avista Capital Partners has acquired Taconic Biosciences, a provider of genetically engineered research models (GEMs) and related services, from H.I.G. Capital. Transaction terms were not disclosed. Founded in 1952 and headquartered in Rensselaer, N.Y., Taconic Biosciences specializes in genetically engineered research models and services, specifically murine models for use in drug discovery […] November 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Proscia presents results on AI melanoma diagnostic predictions Proscia has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer. The findings, presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance. Conducted at […] November 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 J.P. Morgan launches life sciences private capital team J.P. Morgan Asset Management has announced the launch of a new life sciences private equity team, Life Sciences Private Capital. The new team will invest in early and growth stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas. These include genetic […] November 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 First to market doesn’t guarantee success A comparison of two cancer drugs, Opdivo and Keytruda, reveals that being the first-to-market is not necessarily the main factor in a drug’s success. For the first four years since their approval, the anticancer drug Opdivo outperformed Keytruda in sales. But this trend reversed in 2018, with Keytruda’s sales becoming higher than Opdivo’s. Recently, a […] November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Citeline and Norstella merge to create $5B pharma technology company Norstella has announced the completion of its merger with Citeline (formerly Pharma Intelligence). Upon closing, the $5 billion global company is now one of the world’s largest pharma intelligence solutions providers on the market, with more than 1,600 employees across the five brands that make up Norstella: Evaluate, MMIT, Panalgo, The Dedham Group, and now […] November 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email